What TB-500 actually costs in the UK

If you are in the UK trying to find out what TB-500 costs, the honest answer begins with a correction. There is no UK price in the sense there is a price for a licensed medicine. TB-500 holds no marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), the body that licenses medicines for sale in Britain. No authorisation means no NHS list price, no NICE technology appraisal, and no private pharmacy tariff to quote. What exists instead is a grey market of vendors selling it as a research chemical, and the number printed on a vial is not a medicine price at all^[1].

No NHS price, and no NICE appraisal

NHS access to a medicine runs through two gates. An MHRA licence comes first, then a National Institute for Health and Care Excellence (NICE) technology appraisal decides whether the NHS will fund it and for whom. TB-500 has cleared neither. An unlicensed medicine, in the words of the NHS Specialist Pharmacy Service, is any product that meets the definition of a medicine but does not hold a Marketing Authorisation valid in the UK, and it sits outside the MHRA licensing process entirely^[1]. No authorisation means no NICE technology appraisal, no place on an NHS formulary, and therefore no reimbursement pathway.

That matters for the framing many readers arrive with. There is no set of NHS eligibility criteria for TB-500, the way there is for a licensed weight or diabetes drug, because eligibility criteria only exist for products the NHS has agreed to fund. You cannot be approved or refused for something the health service has never assessed. The reimbursement question and the NHS-criteria question both dissolve at the same point: there is no licensed product to reimburse or to set criteria for.

There is one route by which unlicensed medicines do reach UK patients, and it is worth ruling out so nobody assumes it applies here. Pharmacists can supply an unlicensed "special" to meet the particular clinical need of an individual patient when no licensed product will do. That supply happens under prescriber and pharmacist governance, and because unlicensed products are outside the MHRA process, the professionals must take additional steps to assure themselves of the quality, safety and efficacy of what they supply^[1]. That is a controlled clinical exception, not a shop counter. It does not turn the research-chemical version of TB-500 into an off-the-shelf product with a list price, and it is not what online vendors are offering.

The grey market is the only UK price you will see

Because no pharmacy can lawfully sell TB-500 to you as a medicine, the only place a UK buyer sees a number is an online research-chemical vendor. These sites list vials labelled "for research use only" and priced in the region of a few tens of pounds for a 5 mg vial, with multi-vial kits working out cheaper per unit. Shipping from outside the UK can add customs handling and VAT on top. That figure looks small next to a licensed prescription drug, and the reason it looks small is the point of this article: it reflects an unregulated powder, not a quality-assured therapeutic. We cover the wider supply picture in the TB-500 grey-market risks guide.

TB-500 also carries a labelling problem that most grey-market peptides do not. The name is used for two different molecules: the synthetic heptapeptide AC-LKKTETQ (residues 17 to 23 of thymosin beta-4) and the full-length 43-residue thymosin beta-4 peptide itself. The two have very different molecular weights, roughly 889 daltons for the heptapeptide against roughly 4,963 daltons for the full-length protein, and vendors do not always specify which one is in the vial. A buyer paying a grey-market price often cannot confirm which molecule they are purchasing, which makes the price even harder to compare across sellers.

The MHRA is explicit that a medicinal product may not be advertised in the UK where there is no Marketing Authorisation in force^[2]. Vendors work around this with the research-use label, which does not legalise human use and does not put the product through any pharmaceutical quality control. In the UK, TB-500 is best understood as sitting in that gap: not a scheduled controlled drug, but not an authorised medicine either, which is why there is no lawful consumer price for it.

Why the low number is the warning, not the deal

The grey-market price is cheap because it excludes almost everything a medicine licence pays for: identity testing that confirms the vial contains what the label claims, sterility and endotoxin control, dose accuracy, and an assured chain of custody. Unlicensed products are outside the MHRA process, so no agency has verified what is in the vial^[1]. With TB-500's two-molecule ambiguity on top, the identity question is sharper here than for a peptide with a single canonical form, as the TB-500 evidence review sets out in more detail.

The research base underneath the price is thin where it counts. The only Western-standard human trial data for any thymosin beta-4 product sits in ophthalmology. A 2023 Phase 3 trial of RGN-259, a 0.1% thymosin beta-4 eye drop, randomised 18 patients with neurotrophic keratopathy and reported complete corneal healing at four weeks in 6 of 10 treated patients against 1 of 8 on placebo^[3]. That is a small dataset, it is a topical eye drop, and it has nothing to do with the subcutaneous injection sold in the grey market for tendon and muscle recovery.

A 2026 review of peptide therapies for musculoskeletal injuries and athletic performance reached the same conclusion for the injury-recovery use case: many unapproved peptides show favourable tissue-repair outcomes in animal models, but rigorous human safety data are scarce and there is potential for serious harm^[4]. So a UK buyer is paying for a product whose human dose, safety window, and even molecular identity are unestablished for the use most people are considering. A licensed medicine that costs a few hundred pounds a month at least comes with an assurance that the molecule, the dose, and the sterility have been checked. A grey-market vial that costs a fraction of that comes with none of those assurances, and the saving is money not spent on the checks that would make the product safe to put in a body.

The doping and legal overlay on any price

If you compete in any sport under the World Anti-Doping Agency code, the price is beside the point. Thymosin beta-4 and its derivatives, TB-500 named explicitly, were added as examples of prohibited growth factors under section S2.3 of the WADA Prohibited List, with effect from 1 January 2018^[5]. The substance is prohibited in and out of competition. UK Anti-Doping enforces the same WADA Prohibited List, so the ban applies to British athletes exactly as written, and a cheap vial can still cost an athlete a multi-year sanction.

On the supply side, advertising or selling TB-500 for human use in the UK runs into the Human Medicines Regulations, because there is no Marketing Authorisation to permit it^[2]. Simple possession sits in a grey area rather than being a drug-scheduling offence, but commercial sale to consumers is what regulators act against. The low sticker price and the legal exposure are two sides of the same fact: this is not a product the UK system recognises as a medicine.

Where this lands

So the question, what does TB-500 cost in the UK, has two answers that do not meet. The medicine answer is that there is no price, because there is no licensed product to price, no NICE appraisal, and no NHS route. The grey-market answer is a small number on a vial that buys an untested research chemical, and often one whose exact molecule is not even specified, rather than a treatment. For the full regulatory and evidence picture, see TB-500 regulation by country and the UK regulation hub.

This article is for educational and journalistic purposes only and is not medical, legal, or financial advice. Grey-market prices change without notice and regulatory status can change too. If you are considering TB-500, the conversation belongs with a clinician who knows your medical history, not with a vendor's price list. A price tells you what a seller wants for a vial. It tells you nothing about what is in the vial, whether it is safe for you, or whether using it is lawful in your situation, and those are the questions that actually matter. PeptideMethods does not sell, source, or facilitate the sale of any peptide.